{
  "profile_url": "https://www.moffitt.org/research-science/researchers/hyo-han/",
  "last_updated": "2025-11-21T22:50:24.080959",
  "researcher_id": "4650",
  "degrees": [
    "MD"
  ],
  "title": "",
  "primary_program": "breast oncology",
  "research_program": "molecular medicine",
  "overview": "Dr. Han's research focuses on preoperative therapy in breast cancer and racial disparities and breast cancer.",
  "research_interests": [
    "Dr. Han's research focuses on preoperative therapy in breast cancer and racial disparities and breast cancer.\n  *"
  ],
  "associations": [
    "Breast Oncology",
    "Molecular Medicine Program",
    "Cancer Chemoprevention Research Interest Group",
    "Experimental Therapeutics Program"
  ],
  "education": [
    {
      "type": "Medical School",
      "institution": "Seoul University College of Medicine",
      "degree": "MD"
    },
    {
      "type": "Internship",
      "institution": "Seoul National University Hospital",
      "position": "Intern"
    },
    {
      "type": "Residency",
      "institution": "Cleveland Clinic Foundation",
      "position": "Intern",
      "specialty": "al Medicine"
    },
    {
      "type": "Fellowship",
      "institution": "University of Miami/Jackson Memorial Hospital",
      "specialty": "Hematology/Oncology"
    },
    {
      "type": "Board Certification",
      "institution": "Internal Medicine",
      "certification": "Hematology"
    }
  ],
  "publications": [
    {
      "title": "Correction: Comparative efficacy of first- versus second-line CDK4/6 Inhibition in hormone receptor-positive, HER2-negative metastatic breast cancer",
      "pubmed_id": "41131614",
      "pmc_id": "PMC12548101",
      "year": "2025",
      "publication_date": "2025 Oct",
      "authors": "Ravani VL, Bagheri Z, Brufsky AM, Michelon I, O'Regan R, Lustberg M, Han H, Wang M, Wander SA",
      "journal": "Breast Cancer Res"
    },
    {
      "title": "Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer",
      "pubmed_id": "40711480",
      "pmc_id": "PMC12485373",
      "year": "2025",
      "publication_date": "2025 Oct",
      "authors": "Wesolowski R, Rugo HS, Specht JM, Han H, Kabos P, Vaishampayan U, Wander SA, Gogineni K, Spira A, Schott AF, Abu-Khalaf M, Mutka SC, Suzuki S, Sullivan B, Gorbatchevsky I, Layman RM",
      "journal": "Clin Cancer Res"
    },
    {
      "title": "Quantitative habitat concentration analysis of triple negative breast cancer on MRI correlates with pathologic response to combination neoadjuvant immuno/chemotherapy",
      "pubmed_id": "40945432",
      "year": "2025",
      "publication_date": "2025 Nov",
      "authors": "Weinfurtner RJ, Ataya D, Funaro K, Bhatt A, Abdalah M, Stringfield O, Raghunand N, Thompson Z, Lee MC, Czerniecki B, Muller AS, Soliman H, Han H",
      "journal": "Clin Imaging"
    },
    {
      "title": "A pilot study incorporating HER2-directed dendritic cells into neoadjuvant therapy of early stage HER2+ER- breast cancer",
      "pubmed_id": "40097486",
      "pmc_id": "PMC11914126",
      "year": "2025",
      "publication_date": "2025 Mar",
      "authors": "Soliman H, Aldrich A, Abdo N, Han H, Soyano A, Costa R, Armaghani A, Kiluk J, Khakpour N, Lee MC, Hoover S, Laronga C, Niell B, Mooney B, Weinfurtner RJ, Rosa M, Czerniecki B",
      "journal": "NPJ Breast Cancer"
    },
    {
      "title": "Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial",
      "pubmed_id": "40526879",
      "pmc_id": "PMC12184982",
      "year": "2025",
      "publication_date": "2025 Jun",
      "authors": "Wolf DM, Yau C, Campbell M, Glas A, Barcaru A, Mittempergher L, Kuilman M, Brown-Swigart L, Hirst G, Basu A, Magbanua M, Sayaman R, Huppert L, Delson A, Symmans WF, Borowsky A, Pohlmann P, Rugo H, Clark A, Yee D, DeMichele A, Perlmutter J, Petricoin EF, Chien J, Stringer-Reasor E, Shatsky R, Liu M, Han H, Soliman H, Isaacs C, Nanda R, Hylton N, Pusztai L, Esserman L, van 't Veer L",
      "journal": "JCO Precis Oncol"
    },
    {
      "title": "Phase II trial of brain MRI surveillance in stage IV breast cancer",
      "pubmed_id": "39851040",
      "pmc_id": "PMC12309701",
      "year": "2025",
      "publication_date": "2025 Jul",
      "authors": "Ahmed KA, Kim Y, Armaghani AJ, Arrington JA, Costa RL, Czerniecki BJ, Diaz R, Dowell RA, Extermann M, Forsyth PA, Lee KT, Loftus L, Mills MN, Phuoc VH, Rosa M, Soliman HH, Sam CS, Washington IR, Soyano AE, Han HS",
      "journal": "Neurooncol"
    },
    {
      "title": "Cancer-Related Cognitive Impairment and the Potential of Dietary Interventions for the Prevention and Mitigation of Neurodegeneration",
      "pubmed_id": "39570793",
      "year": "2025",
      "publication_date": "2025 Jan",
      "authors": "Crowder SL, Gudenkauf LM, Hoogland AI, Han HS, Small BJ, Carson TL, Parker NH, Booth-Jones M, Jim HSL",
      "journal": "Cancer Res"
    },
    {
      "title": "Alteration of the Tumor Microenvironment With Intratumoral Dendritic Cells Before Chemotherapy in ERBB2 Breast Cancer: A Nonrandomized Clinical Trial",
      "pubmed_id": "39636623",
      "pmc_id": "PMC11622104",
      "year": "2025",
      "publication_date": "2025 Feb",
      "authors": "Han HS, Aldrich AL, Garg SK, Weinfurtner RJ, Nguyen JV, Mo Q, Whiting J, Childress J, Soliman H, Costa R, Armaghani A, Soyano A, Kiluk J, Hoover S, Lee MC, Khakpour N, Shenoi N, Jameel Z, Koski GK, Czerniecki BJ",
      "journal": "JAMA Oncol"
    },
    {
      "title": "Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer",
      "pubmed_id": "39625569",
      "pmc_id": "PMC11785665",
      "year": "2025",
      "publication_date": "2025 Feb",
      "authors": "Rugo HS, Campbell M, Yau C, Jo Chien A, Wallace AM, Isaacs C, Boughey JC, Han HS, Buxton M, Clennell JL, Asare SM, Steeg K, Wilson A, Singhrao R, Matthews JB, Perlmutter J, Fraser Symmans W, Hylton NM, DeMichele AM, Yee D, Van't Veer LJ, Berry DA, Esserman LJ",
      "journal": "Breast Cancer Res Treat"
    },
    {
      "title": "A bedside-to-bench translational analysis of NF1 alterations and CDK4/6 inhibitor resistance in hormone receptor-positive metastatic breast cancer",
      "pubmed_id": "40578027",
      "pmc_id": "PMC12266523",
      "year": "2025",
      "publication_date": "2025 Aug",
      "authors": "Lloyd MR, Chica-Parrado R, Weipert CM, Knepper TC, Podany EL, Napolitano F, Ye D, Lin CC, Uemoto Y, Liao J, Wegrzyn C, Walko CM, Ryan LY, Keenan JC, Medford AJ, Liu SA, Wulf GM, Clifton KK, Ma CX, Han HS, Zhang N, Ellisen LW, Bardia A, Arteaga CL, Hanker AB, Wander SA",
      "journal": "EBioMedicine"
    }
  ],
  "grants": [
    {
      "description": "Title: A Chemotherapy-free Treatment Regimen for HER-2 Positive Breast Cancer utilizing HER2-directed Intratumoral Dendritic Cell Immunotherapy plus Trastuzumab and Pertuzumab   \nAward Number: 25C18  \nSponsor: Florida Department of Health  \nHan, H. (PD/PI)",
      "title": "A Chemotherapy-free Treatment Regimen for HER-2 Positive Breast Cancer utilizing HER2-directed Intratumoral Dendritic Cell Immunotherapy plus Trastuzumab and Pertuzumab",
      "award_number": "25C18",
      "sponsor": "Florida Department of Health",
      "investigators": [
        {
          "name": "Han, H.",
          "role": "PD/PI"
        }
      ]
    }
  ],
  "participating_trials": [
    {
      "trial_url": "https://www.moffitt.org/clinical-trials-and-studies/clinical-trial-17268-b/",
      "trial_id": "17268",
      "title": "I-SPY 2.2 TRIAL - Investigation of Serial Studies to Predict your Therapeutic Response with Imaging and Molecular Analysis 2",
      "condition": "Breast",
      "intervention": "AKTi (); AMP-514 (Durvalumab); ARV-471 (); ARX-788 (); Abemaciclib (); Adriamycin (doxorubicin); Cemiplimab (); DAN-222 (); Datopotamab Deruxtecan (); Dostarlimab (); Durvalumab (); Femara (Letrozole); GSK5733584 (); Herceptin (Trastuzumab); LY2835219 (Abemaciclib); Lasofoxifene (); Letrozole (); MEDI4736 (Durvalumab); Niraparib (); PD-1 (); PD-L1 (); Paraplatin (carboplatin); Pembrolizumab (Keytruda); Pertuzumab (); REGN2810 (Cemiplimab); Rilvegostomig (); Sarilumab (); T-Dxd (); TSR-042 (Dostarlimab); Taxol (paclitaxel); Taxotere (docetaxel); Trastuzumab (); VV1 (); Z-endoxifen (); Zanidatamab (); carboplatin (); cyclophosphamide (); cytoxan (cyclophosphamide); docetaxel (); doxorubicin (); paclitaxel (); rhuMAb HER2 (Trastuzumab)",
      "status": "Open"
    },
    {
      "trial_url": "https://www.moffitt.org/clinical-trials-and-studies/clinical-trial-20915/",
      "trial_id": "20915",
      "title": "Neoadjuvant Therapy of HER2 directed Dendritic Cell (DC1) vaccine Plus Weekly Paclitaxel, Trastuzumab and Pertuzumab in Patients with HER-2 Positive Breast Cancer (NATASHA trial)",
      "condition": "Breast",
      "intervention": "DC1 Vaccine (); Herceptin (Trastuzumab); Pertuzumab (); Taxol (paclitaxel); Trastuzumab (); paclitaxel (); rhuMAb HER2 (Trastuzumab)",
      "status": "Open"
    },
    {
      "trial_url": "https://www.moffitt.org/clinical-trials-and-studies/clinical-trial-21093/",
      "trial_id": "21093",
      "title": "Phase 1/1b/2 Multicenter, Open-Label, First-in-Human Dose Escalation and Dose Expansion Study to Assess Safety and Tolerability of Orally Administered PMD-026 as a Single Agent and in Combination in Patients with Metastatic or Locally Advanced (Inoperable) RSK2+ Breast Cancer",
      "condition": "Breast",
      "intervention": "Faslodex (fulvestrant); PMD-026 (); fulvestrant ()",
      "status": "Open"
    },
    {
      "trial_url": "https://www.moffitt.org/clinical-trials-and-studies/clinical-trial-21378/",
      "trial_id": "21378",
      "title": "Phase 1 Study of Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine and Pepinemab / Trastuzumab in Patients with Metastatic HER2-Positive Breast Cancer",
      "condition": "Breast",
      "intervention": "CD4+ T Cells (); DC1 Vaccine (); Herceptin (Trastuzumab); Pepinemab (VX15/2503); Trastuzumab (); cyclophosphamide (); cytoxan (cyclophosphamide); rhuMAb HER2 (Trastuzumab)",
      "status": "OPEN (SUSPENDED)"
    },
    {
      "trial_url": "https://www.moffitt.org/clinical-trials-and-studies/clinical-trial-21899/",
      "trial_id": "21899",
      "title": "Phase Ib Expansion Study of CX-5461 in Patients with Solid Tumours and BRCA2 and/or PALB2 Mutation",
      "condition": "Multiple",
      "intervention": "CX-5461 ()",
      "status": "Open"
    },
    {
      "trial_url": "https://www.moffitt.org/clinical-trials-and-studies/clinical-trial-22102/",
      "trial_id": "22102",
      "title": "A Phase 1b, First-in-human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants with Solid Tumors",
      "condition": "Multiple",
      "intervention": "XMT-1660 ()",
      "status": "Open"
    },
    {
      "trial_url": "https://www.moffitt.org/clinical-trials-and-studies/clinical-trial-22356/",
      "trial_id": "22356",
      "title": "A Modular Open-Label, Multi-Centre Phase 1/2 Dose-Finding, Optimistation, and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0062 in Patients with Relapsed Locally Advanced or Metastatic AR+/HER2-/ER+ Breast Cancer",
      "condition": "Breast",
      "intervention": "772256 (Palbociclib); Abemaciclib (); Aromasin (Exemestane); EP0062 (); Elacestrant (); Exemestane (); Faslodex (fulvestrant); LEE011 (Ribociclib); LY2835219 (Abemaciclib); Palbociclib (); Ribociclib (); everolimus (RAD001); fulvestrant ()",
      "status": "Open"
    },
    {
      "trial_url": "https://www.moffitt.org/clinical-trials-and-studies/clinical-trial-22515/",
      "trial_id": "22515",
      "title": "Genomic Alterations of PI3K Pathway in HER2-Positive Breast Cancer",
      "condition": "Breast",
      "status": "Open"
    },
    {
      "trial_url": "https://www.moffitt.org/clinical-trials-and-studies/clinical-trial-23249/",
      "trial_id": "23249",
      "title": "PRE-I-SPY TRIAL - PRE-Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis: A Phase I/Ib platform trial",
      "condition": "Breast",
      "intervention": "ALX148 (); Cemiplimab (); REGN2810 (Cemiplimab); T-Dxd (); Tucatinib (); Vidutolimod (); Zanidatamab ()",
      "status": "OPEN (SUSPENDED)"
    },
    {
      "trial_url": "https://www.moffitt.org/clinical-trials-and-studies/clinical-trial-23255/",
      "trial_id": "23255",
      "title": "An Open-Label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of XL309 (ISM3091) as Single-Agent and Combination Therapy in Patients with Advanced Solid Tumors",
      "condition": "Multiple",
      "intervention": "Olaparib (Lynparza); XL309 ()",
      "status": "Open"
    }
  ],
  "lab_page_url": "",
  "google_scholar_url": "",
  "photo_url": "https://www.moffitt.org/globalassets/images/researchers_bio/HanHyo_4650.jpg",
  "contact": {
    "contact_url": "https://eforms.moffitt.org/ContactResearchersForm?PERID=4650"
  },
  "content_hash": "e94680da429fda636bd2ce7af28edc885be810e3b070922624d97159e2f533da",
  "researcher_name": "hyo han",
  "department": ""
}